Last week, Leiter’s 503B outsourcing facility and drug manufacturer Mobius Therapeutics announced a national sales and marketing agreement for Mitosol. Mitosol is the only FDA-approved formulation of mitomycin-C with an ophthalmic indication. Leiter’s is ceasing production of mitomycin-C, as it has been deemed an essential copy, and will instead become a supplier of Mitosol. This agreement is designed to limit supply disruption for Leiter’s customers. Additional information is available in a joint press release.